Redisol side effects, by duration, gender and age (a phase IV clinical study of FDA data)

female:

1. Acute myocardial infarction (acute heart attack)
2. Cardiac arrest

male:

1. Alanine aminotransferase increased
2. Abasia (inability to walk)
3. Atelectasis (partial or complete collapse of the lung)
4. Hyperkalaemia (damage to or disease of the kidney)
5. Hypotonia (low muscle tone)
6. Muscle weakness (a lack of muscle strength)

0-1:

n/a

2-9:

1. Hypotonia (low muscle tone)

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

1. Cardiac arrest

50-59:

n/a

60+:

1. Alanine aminotransferase increased
2. Abasia (inability to walk)
3. Atelectasis (partial or complete collapse of the lung)
4. Acute myocardial infarction (acute heart attack)
5. Hyperkalaemia (damage to or disease of the kidney)
6. Muscle weakness (a lack of muscle strength)

< 1 month:

n/a

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Alanine aminotransferase increased
2. Abasia (inability to walk)
3. Atelectasis (partial or complete collapse of the lung)
4. Acute myocardial infarction (acute heart attack)
5. Cardiac arrest
6. Hyperkalaemia (damage to or disease of the kidney)
7. Hypotonia (low muscle tone)
8. Muscle weakness (a lack of muscle strength)